Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 283

1.

Clinical applications of 68Ga-DOTANOC in neuroendocrine tumours.

Lopci E, Nanni C, Rampin L, Rubello D, Fanti S.

Minerva Endocrinol. 2008 Sep;33(3):277-81. Review.

PMID:
18846030
2.

68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors.

Ambrosini V, Campana D, Bodei L, Nanni C, Castellucci P, Allegri V, Montini GC, Tomassetti P, Paganelli G, Fanti S.

J Nucl Med. 2010 May;51(5):669-73. doi: 10.2967/jnumed.109.071712. Epub 2010 Apr 15.

3.

Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.

Wild D, Bomanji JB, Benkert P, Maecke H, Ell PJ, Reubi JC, Caplin ME.

J Nucl Med. 2013 Mar;54(3):364-72. doi: 10.2967/jnumed.112.111724. Epub 2013 Jan 7.

4.

PET imaging in neuroendocrine tumors: current status and future prospects.

Basu S, Kumar R, Rubello D, Fanti S, Alavi A.

Minerva Endocrinol. 2008 Sep;33(3):257-75. Review.

PMID:
18846029
5.

Gallium-68 PET: a new frontier in receptor cancer imaging.

Al-Nahhas A, Win Z, Szyszko T, Singh A, Nanni C, Fanti S, Rubello D.

Anticancer Res. 2007 Nov-Dec;27(6B):4087-94. Review.

6.

An orthotopic model of pancreatic somatostatin receptor (SSTR)-positive tumors allows bimodal imaging studies using 3T MRI and animal PET-based molecular imaging of SSTR expression.

Stelter L, Amthauer H, Rexin A, Pinkernelle J, Schulz P, Michel R, Denecke T, Stiepani H, Hamm B, Wiedenmann B, Scholz A.

Neuroendocrinology. 2008;87(4):233-42. Epub 2007 Nov 16.

PMID:
18025811
7.

Tumor imaging and therapy using radiolabeled somatostatin analogues.

de Jong M, Breeman WA, Kwekkeboom DJ, Valkema R, Krenning EP.

Acc Chem Res. 2009 Jul 21;42(7):873-80. doi: 10.1021/ar800188e.

PMID:
19445476
8.

68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid.

Ambrosini V, Castellucci P, Rubello D, Nanni C, Musto A, Allegri V, Montini GC, Mattioli S, Grassetto G, Al-Nahhas A, Franchi R, Fanti S.

Nucl Med Commun. 2009 Apr;30(4):281-6. doi: 10.1097/MNM.0b013e32832999c1.

PMID:
19247211
9.

The diagnostic role of 68Ga-DOTATATE PET/CT in the detection of neuroendocrine tumours.

Łapińska G, Bryszewska M, Fijołek-Warszewska A, Kozłowicz-Gudzińska I, Ochman P, Sackiewicz-Słaby A.

Nucl Med Rev Cent East Eur. 2011;14(1):16-20.

10.

Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET.

Fanti S, Ambrosini V, Tomassetti P, Castellucci P, Montini G, Allegri V, Grassetto G, Rubello D, Nanni C, Franchi R.

Biomed Pharmacother. 2008 Dec;62(10):667-71. doi: 10.1016/j.biopha.2008.01.010. Epub 2008 Mar 3.

PMID:
18358680
11.

68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy.

Gabriel M, Oberauer A, Dobrozemsky G, Decristoforo C, Putzer D, Kendler D, Uprimny C, Kovacs P, Bale R, Virgolini IJ.

J Nucl Med. 2009 Sep;50(9):1427-34. doi: 10.2967/jnumed.108.053421. Epub 2009 Aug 18.

12.

The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors.

Kauhanen S, Seppänen M, Ovaska J, Minn H, Bergman J, Korsoff P, Salmela P, Saltevo J, Sane T, Välimäki M, Nuutila P.

Endocr Relat Cancer. 2009 Mar;16(1):255-65. doi: 10.1677/ERC-08-0229. Epub 2008 Dec 16. Erratum in: Endocr Relat Cancer. 2009 Jun;16(2):661.

13.

[Quantification of immunohistochemical expression of somatostatin receptors in neuroendocrine tumors using 68Ga-DOTATATE PET/CT].

Haug AR, Assmann G, Rist C, Tiling R, Schmidt GP, Bartenstein P, Hacker M.

Radiologe. 2010 Apr;50(4):349-54. doi: 10.1007/s00117-009-1972-2. German.

PMID:
20333502
14.

Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.

Putzer D, Gabriel M, Henninger B, Kendler D, Uprimny C, Dobrozemsky G, Decristoforo C, Bale RJ, Jaschke W, Virgolini IJ.

J Nucl Med. 2009 Aug;50(8):1214-21. doi: 10.2967/jnumed.108.060236. Epub 2009 Jul 17.

15.

68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors.

Pettinato C, Sarnelli A, Di Donna M, Civollani S, Nanni C, Montini G, Di Pierro D, Ferrari M, Marengo M, Bergamini C.

Eur J Nucl Med Mol Imaging. 2008 Jan;35(1):72-9. Epub 2007 Sep 14.

PMID:
17874094
16.

Functional imaging of neuroendocrine tumours with PET.

Mottaghy FM, Reske SN.

Pituitary. 2006;9(3):237-42. Review.

PMID:
17036194
17.

68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT.

Kroiss A, Putzer D, Decristoforo C, Uprimny C, Warwitz B, Nilica B, Gabriel M, Kendler D, Waitz D, Widmann G, Virgolini IJ.

Eur J Nucl Med Mol Imaging. 2013 Apr;40(4):514-23. doi: 10.1007/s00259-012-2309-3. Epub 2013 Jan 5.

PMID:
23291643
18.

⁶⁸Ga-DOTANOC PET/CT in patients with carcinoma of unknown primary of neuroendocrine origin.

Naswa N, Sharma P, Kumar A, Soundararajan R, Kumar R, Malhotra A, Ammini AC, Bal C.

Clin Nucl Med. 2012 Mar;37(3):245-51. doi: 10.1097/RLU.0b013e31823ea730.

PMID:
22310250
19.

Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours.

Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schäfer M, Schilling T, Haufe S, Herrmann T, Haberkorn U.

Eur J Nucl Med Mol Imaging. 2007 Oct;34(10):1617-26. Epub 2007 May 23.

PMID:
17520251
20.

Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours.

Ambrosini V, Tomassetti P, Castellucci P, Campana D, Montini G, Rubello D, Nanni C, Rizzello A, Franchi R, Fanti S.

Eur J Nucl Med Mol Imaging. 2008 Aug;35(8):1431-8. doi: 10.1007/s00259-008-0769-2. Epub 2008 Apr 17.

PMID:
18418596
Items per page

Supplemental Content

Write to the Help Desk